Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 56 of the 58 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate glucose-dependent insulinotropic polypeptide (GIP) secretion in patients with type 2 diabetes and nondiabetic control subjects during oral glucose or meal tests. RESEARCH DESIGN AND METHODS: Eligible trials were identified by The Cochrane Library, MEDLINE, Embase, and Web of Science. Data were retrieved and random-effects models for the primary meta-analysis, random-effects meta-regression, and subgroup and regression analyses were applied. RESULTS: Random-effects meta-analysis of GIP responses in 23 trials during 28 different stimulation tests showed that patients with type 2 diabetes (n = 363) exhibited no significant differences (P = not significant) in peak plasma GIP, total area under the curve (tAUC), time-corrected tAUC (tAUC × min−1), and time-corrected incremental area under the curve (iAUC × min−1) in comparison with nondiabetic control subjects (n = 325) but had lower GIP responses as evaluated from iAUC (weighted mean difference, −648 pmol/L × min; 95% CI, −1,276 to −21). Fixed-effects models meta-analyses confirmed most of the results of the primary meta-analysis but showed iAUC × min−1 to be reduced and showed tAUC and tAUC × min−1 to be higher in diabetic patients. Random-effects meta-regression of the primary meta-analysis showed that age (peak GIP, tAUC, iAUC, and iAUC × min−1), BMI (tAUC, iAUC, and iAUC × min−1), and HbA1c (iAUC and iAUC × min−1) predicted some of the GIP outcomes. Post hoc subgroup analysis showed a negative influence of age and of HbA1c on GIP responses and showed a positive influence of BMI on GIP responses. CONCLUSIONS: Our results suggest that patients with type 2 diabetes are characterized by preserved GIP secretion in response to oral glucose and meal tests. They also suggest that high BMI is associated with increased GIP responses but increasing age and HbA1c are associated with reduced GIP secretion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Current research indicates that although GLP-1 secretion is preserved in individuals with T2DM, there is an impairment of GLP-1 function. This includes reduced ability to secrete insulin, heightened insulin resistance, and elevated blood sugar levels, potentially resulting in diminished expression of GLP-1 receptors and developing GLP-1 resistance.10”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [10]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Self-citationReduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
Self-citationNAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
Self-citationLaferrère, B., Heshka, S., Wang, K., Khan, Y., McGinty, J., Teixeira, J., Hart, A. B., & Olivan, B. (2007) · Diabetes Care · doi:10.2337/dc06-1549 · Cited by 532
Self-citationVilsbøll, T., Krarup, T., Sonne, J., Madsbad, S., Vølund, A., Juul, A. G., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021873 · Cited by 528
Self-citationNauck, M. A. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.76.4.912 · Cited by 506
Muscelli, E., Mari, A., Casolaro, A., Camastra, S., Seghieri, G., Gastaldelli, A., Holst, J. J., & Ferrannini, E. (2008) · Diabetes · doi:10.2337/db07-1315 · Cited by 409 · cited 1×
“Many factors previously have been positively associated with GIP responses, including BMI (34,45), female sex (28), and metformin treatment (22).”
BackgroundSelf-citationDeacon, C. F., Nauck, M. A., Meier, J., Hücking, K., & Holst, J. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.10.6855 · Cited by 401
Self-citationHuman duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP
Theodorakis, M. J., Carlson, O., Michopoulos, S., Doyle, M. E., Juhaszova, M., Petraki, K., & Egan, J. M. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00326.2004 · Cited by 396
Downregulation of GLP-1 and GIP Receptor Expression by Hyperglycemia
Xu, G., Kaneto, H., Laybutt, D. R., Duvivier-Kali, V. F., Trivedi, N., Suzuma, K., King, G. L., Weir, G. C., & Bonner-Weir, S. (2007) · Diabetes · doi:10.2337/db06-1033 · Cited by 377
Vollmer, K., Holst, J. J., Baller, B., Ellrichmann, M., Nauck, M. A., Schmidt, W. E., & Meier, J. J. (2008) · Diabetes · doi:10.2337/db07-1124 · Cited by 356
Self-citationGlucose-Dependent Insulinotropic Polypeptide
Christensen, M., Vedtofte, L., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2011) · Diabetes · doi:10.2337/db11-0979 · Cited by 353
Self-citationReduced Incretin Effect in Type 2 Diabetes
Knop, F. K., Vilsbøll, T., Højberg, P. V., Larsen, S., Madsbad, S., Vølund, A., Holst, J. J., & Krarup, T. (2007) · Diabetes · doi:10.2337/db07-0100 · Cited by 349
Self-citationDeacon, C. F. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.10.3575 · Cited by 301
Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes
Holst, J. J., Knop, F. K., Vilsbøll, T., Krarup, T., & Madsbad, S. (2011) · Diabetes Care · doi:10.2337/dc11-s227 · Cited by 280
Self-citationWhat do we know about the secretion and degradation of incretin hormones?
Deacon, C. F. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2004.06.007 · Cited by 241
Wannamethee, S. G., Papacosta, O., Lawlor, D. A., Whincup, P. H., Lowe, G. D., Ebrahim, S., & Sattar, N. (2012) · Diabetologia · doi:10.1007/s00125-011-2284-4 · Cited by 223
Impaired regulation of the incretin effect in patients with type 2 diabetes
Bagger, J. I., Knop, F. K., Lund, A., Vestergaard, H., Holst, J. J., & Vilsbøll, T. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2435 · Cited by 219
Self-citationChanges in Gastric Emptying Rates with Age
Horowitz, M., Maddern, G. J., Chatterton, B. E., Collins, P. J., Harding, P. E., & Shearman, D. J. C. (1984) · Clinical Science · doi:10.1042/cs0670213 · Cited by 217
Knop, F. K., Vilsbøll, T., Madsbad, S., Holst, J. J., & Krarup, T. (2007) · Diabetologia · doi:10.1007/s00125-006-0566-z · Cited by 193
Self-citationAsmar, M., Simonsen, L., Madsbad, S., Stallknecht, B., Holst, J. J., & Bülow, J. (2010) · Diabetes · doi:10.2337/db10-0098 · Cited by 184 · cited 2×
“Besides the renowned insulinotropic effect of GIP, the hormone also exerts glucagonotropic and adipogenic effects (7,8).”
BackgroundSelf-citationRyskjær, J., Deacon, C. F., Carr, R. D., Krarup, T., Madsbad, S., Holst, J., & Vilsbøll, T. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02221 · Cited by 181
Self-citationClements, R. H., Gonzalez, Q. H., Long, C. I., Wittert, G., & Laws, H. L. (2004) · The American Surgeon · doi:10.1177/000313480407000101 · Cited by 176
Salinari, S., BERTUZZI, A., Asnaghi, S., Guidone, C., Manco, M., & Mingrone, G. (2008) · Diabetes Care · doi:10.2337/dc08-1314 · Cited by 172
Romero, F., Nicolau, J., Flores, L., Casamitjana, R., Ibarzabal, A., Lacy, A., & Vidal, J. (2012) · Surgical Endoscopy · doi:10.1007/s00464-012-2166-y · Cited by 165
Vaag, A. A., Holst, J. J., Vølund, A., & Beck‐Nielsen, H. (1996) · European Journal of Endocrinology · doi:10.1530/eje.0.1350425 · Cited by 154
Self-citationPancreatic Function, Type 2 Diabetes, and Metabolism in Aging
Gong, Z., & Muzumdar, R. H. (2012) · International Journal of Endocrinology · doi:10.1155/2012/320482 · Cited by 154
Physiology of Incretins in Health and Disease
Deacon, C. F., & Åhrén, B. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.293 · Cited by 146
Hypersecretion of Gastric Inhibitory Polypeptide Following Oral Glucose in Diabetes Mellitus
Ross, S. A., Brown, J. C., & Dupré, J. (1977) · Diabetes · doi:10.2337/diab.26.6.525 · Cited by 135
Bose, M., Teixeira, J. A., Oliván, B., Bawa, B., Arias, S., Machineni, S., Pi‐Sunyer, F. X., Scherer, P. E., & Laferrère, B. (2009) · Journal of Diabetes · doi:10.1111/j.1753-0407.2009.00064.x · Cited by 124
Self-citationSalera, M., Giacomoni, P., Pironi, L., Cornia, G. L., Capelli, M., Marini, A. M., Benfenati, F., Miglioli, M., & Barbara, L. (1982) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-55-2-329 · Cited by 118
Solomon, T. P. J., Haus, J. M., Kelly, K. R., Rocco, M. B., Kashyap, S., & Kirwan, J. P. (2010) · Diabetes Care · doi:10.2337/dc09-2021 · Cited by 114
Effects of Diet Soda on Gut Hormones in Youths With Diabetes
Brown, R. J., Walter, M. F., & Rother, K. I. (2012) · Diabetes Care · doi:10.2337/dc11-2424 · Cited by 110
Krarup, T., & Holst, J. J. (1984) · Regulatory Peptides · doi:10.1016/0167-0115(84)90005-3 · Cited by 109
Self-citationJones, I. R., Owens, D. R., Luzio, S. D., Williams, S. E. I., & Hayes, T. M. (1989) · Diabetologia · doi:10.1007/bf00274255 · Cited by 101
Gastric Inhibitory Polypeptide (GIP) in Maturity-onset Diabetes Mellitus
Crockett, S. E., Mazzaferri, E. L., & Cataland, S. (1976) · Diabetes · doi:10.2337/diab.25.10.931 · Cited by 90
Meneilly, G. S., Demuth, H. U., McIntosh, C. H. S., & Pederson, R. A. (2000) · Diabetic Medicine · doi:10.1046/j.1464-5491.2000.00236.x · Cited by 85
Intact Glucagon-like Peptide-1 Levels are not Decreased in Japanese Patients with Type 2 Diabetes
LEE, S., YABE, D., NOHTOMI, K., TAKADA, M., MORITA, R., SEINO, Y., & HIRANO, T. (2010) · Endocrine Journal · doi:10.1507/endocrj.k09e-269 · Cited by 73
GIP-(3–42) does not antagonize insulinotropic effects of GIP at physiological concentrations
Deacon, C. F., Plamboeck, A., ROSENKILDE, M. M., de Heer, J., & Holst, J. J. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00577.2005 · Cited by 72
Self-citationEffects of meal size and composition on incretin, α-cell, and β-cell responses
Rijkelijkhuizen, J. M., McQuarrie, K., Girman, C. J., Stein, P. P., Mari, A., Holst, J. J., Nijpels, G., & Dekker, J. M. (2009) · Metabolism · doi:10.1016/j.metabol.2009.07.039 · Cited by 67
Self-citationResponses and molecular heterogeneity of IR-GIP after intraduodenal glucose and fat
Krarup, T., Holst, J. J., & Larsen, K. L. (1985) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1985.249.2.e195 · Cited by 58
Self-citationHøjberg, P. V., Vilsbøll, T., Zander, M., Knop, F. K., Krarup, T., Vølund, A., Holst, J. J., & Madsbad, S. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02579.x · Cited by 56
Self-citationEffect of Aging and Diabetes on the Enteroinsular Axis
Korosi, J., McIntosh, C. H. S., Pederson, R. A., Demuth, H., Habener, J. F., Gingerich, R. L., Egan, J. M., Elahi, D., & Meneilly, G. S. (2001) · The Journals of Gerontology Series A · doi:10.1093/gerona/56.9.m575 · Cited by 50
Similar incretin secretion in obese and non-obese Japanese subjects with type 2 diabetes
Kozawa, J., Okita, K., Imagawa, A., Iwahashi, H., Holst, J. J., Yamagata, K., & Shimomura, I. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.01.134 · Cited by 36
Self-citationFukase, N., Manaka, H., Sugiyama, K., Takahashi, H., Igarashi, M., Daimon, M., Yamatani, K., Tominaga, M., & Sasaki, H. (1995) · Acta Diabetologica · doi:10.1007/bf00838486 · Cited by 36
PETROFSKY, J. S., Berk, L., & Alnakhli, H. H. (2012) · Experimental Diabetes Research · doi:10.1155/2012/657103 · Cited by 35
Meal test for glucose-dependent insulinotropic peptide (GIP) in obese and type 2 diabetic patients
Škrha, J., Hilgertová, J., Jarolimkova, M., Kunešová, M., & Hill, M. (2010) · Physiological Research · doi:10.33549/physiolres.931893 · Cited by 22
Mazzaferri, E. L., Starich, G. H., Lardinois, C. K., & BOWEN, G. D. (1985) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-61-2-313 · Cited by 21
Osei, K., Falko, J. M., O’Dorisio, T. M., Fields, P. G., & Bossetti, B. M. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-62-2-325 · Cited by 20
Incretin secretion and serum DPP-IV activity in Korean patients with type 2 diabetes
Han, S. J., Kim, H. J., Choi, S., KANG, Y. Y., Lee, K. W., & Kim, D. J. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.06.004 · Cited by 20
COXE, J. S., O’Dorisio, T. M., Cataland, S., & Crockett, S. E. (1981) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-52-5-1002 · Cited by 20
Gastric Inhibitory Polypeptide (GIP) Response in Diabetes Using a Highly Specific Antiserum
Alam, M. J., Kerr, J. I., Cormican, K., & Buchanan, K. D. (1992) · Diabetic Medicine · doi:10.1111/j.1464-5491.1992.tb01835.x · Cited by 19
Gastric Inhibitory Polypeptide Response to Hyper- and Hypoglycemia in Insulin-Dependent Diabetics*
REYNOLDS, C., TRONSGARD, N., GIBBONS, E., BLIX, P. M., & Rubenstein, A. H. (1979) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-49-2-255 · Cited by 18
Groop, P., Fyhrquist, F., & Groop, L. (1985) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365518509160983 · Cited by 7
Research works printed but not linked: 1
- Nasteska, 2012, Lowering GIP secretion has beneficial role in reducing obesity and insulin resistance without impairing glucose tolerance and osteogenesis, Diabetologia, 55, S80
Cited by
Incretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
Nauck, M. A., & Meier, J. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00482-9 · Cited by 503
Nauck, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12591 · Cited by 429
“Recent meta-analyses did not reveal systematic differences in GLP-1 or GIP secretion between healthy subjects and patients with T2D [10,12].”
BackgroundGLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.123 · Cited by 407
Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
Hinnen, D. (2017) · Diabetes Spectrum · doi:10.2337/ds16-0026 · Cited by 394
“The most recent understanding of this deficit suggests that it relates to deterioration of the GLP-1 effect, with impaired capacity to secrete insulin, increasing insulin resistance, and hyperglycemia, perhaps leading to a decrease in GLP-1 receptor expression and resulting in GLP-1 resistance (7).”
Background
Metadata
- Authors
- Calanna, S., Christensen, M., Holst, J. J., Laferrère, B., Gluud, L. L., Vilsbøll, T., & Knop, F. K.
- Affiliations
- University of Copenhagen (DK)
- St. Luke's-Roosevelt Hospital Center (US)
- Corresponding author
- Knop, Filip K.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-09-14
- Volume
- 36
- Issue
- 10
- Pages
- 3346-3352
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3781498
- OpenAlex
- W2079429014
- Cited by
- 158
- References
- 58
- Citations by year
- 2026: 7 · 2025: 8 · 2024: 17 · 2023: 11 · 2022: 13 · 2021: 10 · 2020: 13 · 2019: 13 · 2018: 14 · 2017: 17 · 2016: 11 · 2015: 11 · 2014: 12 · 2013: 1
- FWCI
- 1.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Novo Nordisk Fonden (NNF12OC1015904)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK026687)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucose-dependent insulinotropic polypeptide, GIP secretion, type 2 diabetes, oral glucose tolerance test, test meal, incretin response, body mass index, age, HbA1c, insulin secretion
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 2, Female, Gastric Inhibitory Polypeptide, Glucose Tolerance Test, Humans, Male
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.